The startup operates a theragnostic platform that utilizes clinical testing and molecular mapping to develop precision cannabinoid-based drugs for neurological disorders. This approach enables healthcare institutions and companies to implement personalized treatment strategies, enhancing patient outcomes through targeted drug development solutions.
Funding
$3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug development and testing for neurological disorders often relies on animal models or 2D cell cultures, which fail to accurately replicate the complexity of the human brain, leading to ineffective treatments and high failure rates in clinical trials. Existing methods for studying neurological diseases lack fully ethical, humane, and scalable solutions for pharmaceutical companies to perform neuro-clinical testing.
Solution
CanniOasis offers a human midbrain organoid platform for accelerating the development of precision cannabinoid-based drugs for neurological disorders. The platform utilizes 3D brain cell structures derived from induced pluripotent stem cells (iPSCs) to mimic the natural environment of the human brain, enabling more accurate study of cellular behaviors and interactions. This approach allows for proprietary drug screening, validation technologies, and drug development strategies, supported by MicroRNA (MiRNA) and epigenetics, to develop proprietary drug screening platforms for cannabinoid-based treatments of neurological diseases, supported by Artificial Intelligence. The company leverages advanced drug delivery formulations to maximize drug effectiveness by targeting specific tissues with precision.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare organizations involved in drug discovery and development for neurological disorders such as Autism, Chronic Pain, Parkinson’s disease, and Epilepsy.
Features
- First-in-the-world human midbrain organoid platform for neurological research
- 3D brain cell structures from stem cells that replicate midbrain cells
- Human midbrain-like organoids (hMLOs) that display neuromelanin granules and key characteristics similar to human midbrain tissue
- Proprietary drug screening platforms for cannabinoid-based treatments of neurological diseases, supported by MicroRNA (MiRNA) and epigenetics
- Advanced drug delivery formulations to maximize drug effectiveness by targeting specific tissues with precision
- Fully functional laboratory for clinical trial technology
- Capabilities for advanced purification techniques to extract minor cannabinoids for pharmaceutical-grade excellence in cultivation